galegenimab：視網膜地圖狀萎縮藥開發難？羅氏撤二期候選抗體藥

A Study Assessing the Safety

https://clinicaltrials.gov

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 ...

Anti

https://www.abeomics.com

Anti-HTRA1(galegenimab biosimilar) mAb ; Clonality : Monoclonal ; Reactivity : Human ; Amount : 100 µg ; Isotype : IgG1 ; Purification : Purified from cell culture ...

Galegenimab (FHTR 2163)

https://www.medchemexpress.com

Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular ...

Galegenimab - Genentech

https://adisinsight.springer.c

Galegenimab (formerly RO 7171009) intravitreal injection was being developed by Genentech (a subsidiary of Roche), for the treatment of patients with ...

galegenimab

https://www.guidetopharmacolog

Comment: Galegenimab is the INN that has been assigned to Genentech's anti-HTRA1 (HtrA serine peptidase 1) Fab antibody [6]. The antibody and its use are ...

VIDEO

https://www.healio.com